A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy

NCT ID: NCT02368652

Last Updated: 2023-05-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 181 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-12-31
• Study Completion Date: 2015-11-30

Brief Summary

Compare the safety and efficacy of amlodipine besylate and candesartan cilexetil combination therapy on patients of essential hypertension who are not properly controlled by candesartan cilexetil monotherapy.

Conditions

Essential Hypertension

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

CC 16mg

Candesartan ceilexetil 16mg, once a day for 8 weeks

Group Type: EXPERIMENTAL

Candesartan cilexetil 16mg

Intervention Type: DRUG

Daily oral administration for 8 weeks

AML 10mg / CC 16mg

Amlodipine 10mg and Candesartan ceilexetil 16mg, once a day for 8 weeks

Group Type: EXPERIMENTAL

Amlodipine 10mg, Candesartan cilexetil 16mg

Intervention Type: DRUG

Daily oral administration for 8 weeks

Interventions

Candesartan cilexetil 16mg

Daily oral administration for 8 weeks

Intervention Type: DRUG

Amlodipine 10mg, Candesartan cilexetil 16mg

Daily oral administration for 8 weeks

Intervention Type: DRUG

Other Intervention Names

Atacand 16mg; Norvasc 10mg, Atacand 16mg

Eligibility Criteria

Inclusion Criteria

• Male or female aged ≥ 19 and ≤ 75 years old
• Subject with essential hypertension
• Subject who have voluntarily agreed to participate in the trial and signed the written informed consent form, after having listened to the purpose, method, and effect of the clinical trial

Exclusion Criteria

• Subject who is siDBP ≥ 120 mmHg or siSBP ≥ 200 mmHg at Visit 1 (screening)
• Subject with difference in the mean blood pressure of over 10 mmHg for siDBP or 20 mmHg for siSBP between both arms at the screening visit
• Subject with known or suspected secondary hypertension [Including but not limited to any of the following: renovascular diseases, adrenal medullary and cortical hyperfunctions, coarctation of the aorta, primary hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's syndrome, pheochromo-cytoma, polycystic kidney disease, etc.]
• Subject with symptomatic orthostatic hypotension(a sudden fall in siDBP of at least 10 mmHg or siSBP of at least 20 mmHg after standing compared with blood pressure from the sitting or supin position)
• Subject with type 1 or type 2 diabetes mellitus with poor glucose control (defined as subject on inculin treatment, with HbA1c > 9.0% or with a modification in the oral anti-hyperglycemic medication regiment within the past 12 weeks prior to visit 1)
• Subject with severe heart disease(congestive heart failure(NYHA class 3 or 4), ischemic heart disease within the past 6 months(unstable angina, myocardial infarction), peripheral blood vascula disease, history of Percutaneous Transluminal Coronary Angioplasty or coronary artery bypass grafting)
• Subject with clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically significant arrhythmia
• Subject with hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, haemodynamically relevant stenosis of the aortic or mitral valve
• Subject with cardiogenic shock
• Subject with severe cerebrovascular disease (history of stroke, cerebral infraction, or cerebral hemorrhage within the past 6 months)
• Subject with a history of or ongoing wasting disease, autoimmune diseases(rheumatoid arthritis, systemic lupus erythematosus, etc.) or connective tissue disease
• Subject with known moderate or malignant retinopathy (history of retinal signs of hemorrhage, visual impairment, retinal microaneurysm etc. within the past 6 months)
• Subject with any surgical or medical condition of the gastrointestinal tract that might sugnificantly alter the absorption, distribution, metabolism or excretion of the drug
• Subject with a history of malignant tumors including leukemia and lymphoma within the past 5 yesrs(except for localized basal cell carcinoma of the skin)
• Subject with any chronic inflammatory condition needing chronic anti-inflammatory therapy
• Subject with chronic kidney disase on dialysis
• Subject with the following clinically significant laboratory abnormalities:

• AST or ALT > 3 x Upper Limit Normal(ULN)
• Serum Creatinine > 1.5 ULN
• Serum potassium < 3.5 mmol/L or > 5.5mmol/L
• Subject requiring concomitant use of other antihypertensive or contraindicated drugs during the entire study period
• Subject with known or suspected contraindications, including history of allergy or hypersensitivity to ARB or dihydropyridine derivatives
• Subject who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or ARB
• Pregnant women or lactating mother, women suspected of being pregnant, women who wish to be pregnant during the study or women of child-bearing potential who are not using medically acceptable methods of contraception (oral contraceptinve, intra-uterine device, condom, etc.), except for women with surgical sterilization. Pre-menopausal women who are not surgically sterilized must have a negative pregnancy test result at Visit1 and maintain acceptable methods of contraception throughout the study. preiodic abstinence (eg. symptothermal, calendar, post-ovulation methods), or hormonal contraceptive are not acceptable methods of contraception
• History of drug or alcohol abuse within the past 1 year
• Use of other investigational products within the past 4 weeks
• Subject who are jdged unsuitable to participate in the study in the opinion of the investigator

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

HK inno.N Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Seungjae Tahk

Role: PRINCIPAL_INVESTIGATOR

Ajou University School of Medicine

Locations

Hallym University Sungsim Hospital

Anyang-si, , South Korea

Inje University Busan Baik Hospital

Busan, , South Korea

Inje University Haeundae Baik Hospital

Busan, , South Korea

Yeungnam University Medical Center

Daegu, , South Korea

Chonnam National University Hospital

Gwangju, , South Korea

Inje University Ilsan Baik Hospital

Ilsan, , South Korea

Inha University Hospital

Incheon, , South Korea

Seoul National University Bundang Hospital

Seongnam-si, , South Korea

Asan Medical Center

Seoul, , South Korea

Ewha Womans University Mokdong Hospital

Seoul, , South Korea

Gangbuk Samsung Hospital

Seoul, , South Korea

Korea University Anam Hospital

Seoul, , South Korea

Korea University Guro Hospital

Seoul, , South Korea

Seoul Medical Center

Seoul, , South Korea

Seoul St. Mary's Hospital Catholic University

Seoul, , South Korea

Soonchunhyang University Hospital

Seoul, , South Korea

Yonsei University Severance Hospital

Seoul, , South Korea

Ajou University Hospital

Suwon, , South Korea

Wonju Severance Christian Hospital

Wŏnju, , South Korea

Countries

South Korea

Other Identifiers

CJ_CCA_301A

Identifier Type: -

Identifier Source: org_study_id